세포 계수 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the cell counting market size was valued at USD 11.54 billion in 2025 and estimated to grow from USD 12.39 billion in 2026 to reach USD 17.71 billion by 2031, at a CAGR of 7.40% during the forecast period (2026-2031).

This report is Segmented by Product Type (Instruments [Spectrophotometers, Flow Cytometers, and More] and Consumables), Application (Research [Cancer Research, and More], Clinical & Diagnostic, and More), End User (Hospitals & Clinical Labs, Academic Institutes, and More), Technology (Flow Cytometry, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cell Counting Market Trends and Insights

Growing Use of High-throughput Flow Cytometry & Automated Hematology Analyzers

New spectral flow cytometers such as Beckman Coulter's CytoFLEX mosaic offer 88 detection channels and nanoparticle sensitivity down to 80 nm, enabling deep immunophenotyping that exceeds the limits of traditional 10-color panels. Spectral unmixing algorithms remove complex compensation steps and shrink operator training requirements, while automated hematology systems from Sysmex and Siemens Healthineers integrate coagulation and immunology modules to streamline consolidated testing workflows. Combined, these platforms reduce sample hand-offs, lower error rates, and allow labs to scale routine counts and specialized assays on a single software spine.

Rising Adoption of AI-powered Image-based Cell Counters for Regenerative Medicine

Machine learning-enabled image analysis drives consistent enumeration even when operators vary in skill. The Singapore-MIT Alliance for Research and Technology showed that UV absorbance spectroscopy paired with AI detects microbial contamination in 30 minutes versus 14 days for sterility culture tests. NanoEntek's fluorescence-based counters differentiate live and dead CAR T cells from tiny sample volumes, trimming reagent costs and supporting precise dosing. Deep learning libraries built on diverse donor samples adapt to different culture conditions, solving historical challenges caused by clumping and debris.

High Cost of Advanced Cell Counting Systems & Maintenance

Spectral flow cytometers can exceed USD 500,000, and annual service contracts often add 10-15% of purchase price. Core facility surveys confirm that upkeep competes with funding for new assays, pressing labs to stagger upgrades or share instruments. Smaller clinics in emerging economies face steeper barriers because manufacturer service hubs cluster around major urban centers.

Other drivers and restraints analyzed in the detailed report include:

1. Integration of Microfluidic Lab-on-a-chip Cell Counting in Point-of-care Testing
2. Expansion of Single-use Bioprocessing Driving Demand for Real-time Viable Cell Density Monitoring
3. Shortage of Skilled Technicians in Low-income Regions

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Consumables captured 54.85% of cell counting market share in 2025 and are tracking a 7.14% CAGR toward 2031. Reagents, assay kits, sera, and single-use sensors are reordered continuously, unlike instruments whose purchases are episodic. The shift to disposable bioreactors reinforces this dynamic because every new batch requires a fresh set of sterile bags, tubing, and media supplements. Within consumables, specialized growth media tailored for stem-cell expansion command premium pricing due to stringent purity requirements, while viability assay kits that combine fluorometric stains with apoptotic markers are displacing trypan-blue methods. Instruments, although a smaller revenue pool, set the installed-base foundation that fuels downstream consumables. Spectrophotometers remain ubiquitous in academia for quick density checks, yet multiparametric flow cytometers and image-based counters are becoming indispensable in therapy production suites where morphology, viability, and phenotype must be tracked in parallel.

The installed fleet of automated cell counters is splitting along two innovation tracks. Image-based models leverage high-resolution CMOS sensors and cloud analytics to return confluence, viability, and morphology readouts in under 30 seconds, while impedance-based devices offer label-free counts ideal for hematopoietic stem cell transplants where minimal manipulation is vital. Microfluidic chip counters further promise to reduce reagent volumes by orders of magnitude, making them attractive for high-cost cell therapy batches that cannot spare large sample volumes. As instrument vendors adopt pay-per-use cloud licenses, laboratories in budget-constrained settings gain entry without large capital outlays, yet long-term cost of ownership remains tied to consumables subscription models embedded in reagent cartridges.

Research activities maintained 40.10% of 2025 revenue as oncology, immunology, and vaccine programs continue to absorb high-throughput platforms. Tumor organoid screening requires precise seeding densities and viability confirmation before drug dosing, while CRISPR screens depend on accurate counts to normalize editing efficiencies. Clinical diagnostics, though smaller in absolute terms, will outpace research by growing at 7.55% CAGR as hospitals automate hematology lines and deploy point-of-care analyzers capable of providing differential counts within five minutes of finger-stick collection. Digital smear analysis cuts pathologist review time, enhancing diagnostic throughput during seasonal surges of hematologic testing.

Industrial and bioprocess segments are advancing as real-time viable cell density becomes mandatory for both fed-batch and continuous perfusion modes. Raman and capacitance sensors feed closed-loop controllers that adjust glucose or lactate feeds to stabilize metabolic profiles, mitigating batch-to-batch variability. Environmental testing has emerged as a niche, with breweries and water-treatment plants adopting rapid microfluidic counters to detect microbial contamination faster than plate counts. Combined, these trends ensure diversified demand so that no single application dominates the cell counting market.

Complete Report Scope:

• By Product Type
  • Instruments
    • Spectrophotometers
    • Flow Cytometers
    • Hematology Analyzers
    • Automated Cell Counters
      • Image-based Cell Counters
      • Impedance Cell Counters
    • Microfluidic Chip Counters
  • Consumables
    • Media, Sera & Reagents
    • Assay Kits
    • Others
• By Application
  • Research
    • Cancer Research
    • Stem-Cell & Regenerative Medicine
    • Immunology & Infectious-Disease
    • Drug Discovery & Toxicology
  • Clinical & Diagnostic
    • Hematology Diagnostics
    • Point-of-Care Testing
  • Industrial & Bioprocess
    • Biopharmaceutical Manufacturing
    • Food & Beverage Quality-Control
    • Environmental Monitoring
• By End User
  • Hospitals & Clinical Labs
  • Research & Academic Institutes
  • Pharmaceutical & Biotech Companies
  • CROs & CMOs
  • Other Industrial Labs
• By Technology
  • Flow Cytometry
  • Image-Based Cytometry
  • Spectrophotometry
  • Impedance (Coulter Principle)
  • Microfluidics & Lab-on-Chip
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the cell counting market with 39.20% revenue share in 2025 on the back of a mature biopharmaceutical manufacturing base, heavy federal research funding, and quick integration of next-generation cytometry in clinical pathways. The United States benefits from FDA device-clearance momentum for automated hematology and home-use differential counters, encouraging hospitals and at-home care providers to adopt advanced platforms. Canada's public health labs deploy image-based systems for hematologic malignancy surveillance, while Mexico's growing medical-device import incentives widen access to mid-range analyzers. Across the region, integrated service networks ensure downtime is minimal, strengthening customer loyalty to incumbent vendors.

Asia-Pacific is the fastest-growing territory, projected at 7.66% CAGR, underpinned by China's push to localize cell therapy supply chains and Japan's expedited regulatory routes for regenerative-medicine products. Government grants fund the build-out of GMP suites, each anchored by high-throughput counters that guarantee process consistency. South Korea, leveraging its biosimilar leadership, invests in continuous perfusion plants where real-time capacitance probes guard against culture crashes. India's vaccine hubs adopt low-cost microfluidic instruments, pairing them with digital dashboards to satisfy stringent batch-release documentation. Australia's translational institutes emphasize point-of-care deployment in remote communities, fostering demand for rugged field analyzers.

1. Danaher
2. Thermo Fisher Scientific
3. Becton Dickinson & Co.
4. Sysmex Corp.
5. Merck KGaA (MilliporeSigma)
6. Agilent Technologies (Nexcelom)
7. Bio-Rad Laboratories
8. Siemens Healthineers
9. Roche
10. PerkinElmer
11. GE Healthcare
12. Tecan Group
13. DeNovix
14. Chemometec A/S
15. Logos Biosystems
16. Countstar (Shanghai Ruiyu)
17. Orflo Technologies
18. Luminex (DiaSorin)
19. Abbott Laboratories
20. HORIBA Medical
21. Mindray Bio-medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Incidence of Target Diseases & Blood Disorders
  • 4.2.2 Growing Use of High-throughput Flow Cytometry & Automated Hematology Analyzers
  • 4.2.3 Rising Adoption of AI-powered Image-based Cell Counters for Regenerative Medicine
  • 4.2.4 Integration of Microfluidic Lab-on-a-chip Cell Counting in Point-of-care Testing
  • 4.2.5 Expansion of Single-use Bioprocessing Driving Demand for Real-time Viable Cell Density Monitoring
  • 4.2.6 Emergence of Label-free Impedance-based Cytometry for Rapid QC in Cell Therapy Manufacturing
• 4.3 Market Restraints
  • 4.3.1 High Cost of Advanced Cell Counting Systems & Maintenance
  • 4.3.2 Shortage of Skilled Technicians in Low-income Regions
  • 4.3.3 Standardization Gaps in Digital Cell-imaging Analytics Hindering Cross-lab Reproducibility
  • 4.3.4 Data-integrity Compliance Burdens Slowing Cloud-connected Device Rollout
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product Type
  • 5.1.1 Instruments
    • 5.1.1.1 Spectrophotometers
    • 5.1.1.2 Flow Cytometers
    • 5.1.1.3 Hematology Analyzers
    • 5.1.1.4 Automated Cell Counters
      • 5.1.1.4.1 Image-based Cell Counters
      • 5.1.1.4.2 Impedance Cell Counters
    • 5.1.1.5 Microfluidic Chip Counters
  • 5.1.2 Consumables
    • 5.1.2.1 Media, Sera & Reagents
    • 5.1.2.2 Assay Kits
    • 5.1.2.3 Others
• 5.2 By Application
  • 5.2.1 Research
    • 5.2.1.1 Cancer Research
    • 5.2.1.2 Stem-Cell & Regenerative Medicine
    • 5.2.1.3 Immunology & Infectious-Disease
    • 5.2.1.4 Drug Discovery & Toxicology
  • 5.2.2 Clinical & Diagnostic
    • 5.2.2.1 Hematology Diagnostics
    • 5.2.2.2 Point-of-Care Testing
  • 5.2.3 Industrial & Bioprocess
    • 5.2.3.1 Biopharmaceutical Manufacturing
    • 5.2.3.2 Food & Beverage Quality-Control
    • 5.2.3.3 Environmental Monitoring
• 5.3 By End User
  • 5.3.1 Hospitals & Clinical Labs
  • 5.3.2 Research & Academic Institutes
  • 5.3.3 Pharmaceutical & Biotech Companies
  • 5.3.4 CROs & CMOs
  • 5.3.5 Other Industrial Labs
• 5.4 By Technology
  • 5.4.1 Flow Cytometry
  • 5.4.2 Image-Based Cytometry
  • 5.4.3 Spectrophotometry
  • 5.4.4 Impedance (Coulter Principle)
  • 5.4.5 Microfluidics & Lab-on-Chip
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Danaher (Beckman Coulter)
  • 6.3.2 Thermo Fisher Scientific, Inc.
  • 6.3.3 Becton Dickinson & Co.
  • 6.3.4 Sysmex Corp.
  • 6.3.5 Merck KGaA (MilliporeSigma)
  • 6.3.6 Agilent Technologies (Nexcelom)
  • 6.3.7 Bio-Rad Laboratories
  • 6.3.8 Siemens Healthineers
  • 6.3.9 F. Hoffmann-La Roche
  • 6.3.10 PerkinElmer
  • 6.3.11 GE HealthCare
  • 6.3.12 Tecan Group
  • 6.3.13 DeNovix
  • 6.3.14 Chemometec A/S
  • 6.3.15 Logos Biosystems
  • 6.3.16 Countstar (Shanghai Ruiyu)
  • 6.3.17 Orflo Technologies
  • 6.3.18 Luminex (DiaSorin)
  • 6.3.19 Abbott Diagnostics
  • 6.3.20 HORIBA Medical
  • 6.3.21 Mindray Bio-medical

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment